Event context and recent share performance DexCom (DXCM) shares have been under pressure recently, with the stock down about 3% over the past month and 8.6% over the past 3 months, while the business ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance. DexCom's steep valuation is only justifiable with sustained ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical technology company focused on continuous glucose monitoring (CGM ...

DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

Dexcom develops continuous glucose monitoring (CGM) devices. Diabetic patients use these to track their glucose levels in ...

At long last, Dexcom's Share app, which allows users to view and share data from their G5 continuous glucose monitors, will be available for Android users. The Android app just now received FDA ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Dexcom, Inc. (NASDAQ:DXCM) stands against the other ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...